Suchergebnisse - "Hiranuma, Osamu"

PubPharm (58)

1

Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC : A Prospective Study

enthalten in: JTO clinical and research reports | 2024

von Katayama, Y. | Yamada, T. | Morimoto, K. | +17

2

Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Morimoto, K. | Yamada, T. | Sawada, R. | +15

3

Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases : A Multicenter, Open-Label Single-Arm Phase II Trial

enthalten in: The oncologist | 2023

von Tanimura, K. | Uchino, J. | Kimura, H. | +11

4

Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer

enthalten in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2023

von Morita-Tanaka, S. | Miyagawa-Hayashino, A. | Yamada, T. | +11

CommentIn: Support Care Cancer. 2023 Aug 1;31(8):500. - PMID 37526795

5

Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer

enthalten in: Supportive care in cancer | 2023

von Morita-Tanaka, S. | Miyagawa-Hayashino, A. | Yamada, T. | +11

6

Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer

enthalten in: Supportive care in cancer | 2023

von Morita-Tanaka, S. | Miyagawa-Hayashino, A. | Yamada, T. | +11

7

TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma : A Prospective Observational Study

enthalten in: JTO clinical and research reports | 2023

von Katayama, Y. | Yamada, T. | Morimoto, K. | +17

8

High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib

enthalten in: Cancer science | 2023

von Yoshimura, A. | Yamada, T. | Serizawa, M. | +25

9

Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations

enthalten in: Proteomes | 2023

von Noguchi, R. | Yoshimura, A. | Uchino, J. | +7

10

High levels of AXL expression in untreated EGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib

enthalten in: Cancer Science | 2023

von Yoshimura, A. | Yamada, T. | Serizawa, M. | +25

1
2
3
4
5
6
Nächster »
[6]